Atossa Genetics Files Again for IPO

Feb 14, 2012

NEW YORK (GenomeWeb News) – Almost one year to the day after pulling a planned initial public offering, Seattle-based Atossa Genetics has refiled with US regulators to go public.

In a Form S-1 filed Feb. 13 with the US Securities and Exchange Commission Atossa said it seeks to sell 1 million shares of its common stock at a price of between $5 and $7 per share, raising up to a little more than $8 million.

The company plans to list on the Nasdaq Capital Market under ticker symbol "ATOS."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Not Mentioning It

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

Lost Some Value There

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

Slight Budget Trim

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

This Week in PLOS

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.

Featured White Papers

Potential Pitfalls to Life Science Product Launch

Freeze-drying - a manufacturing approach to increase the stability of in vitro diagnostic (IVD) assays

Dec

11

Featured Webinar

Assessing the Impact of Different Aneuploid Findings with Independent NGS Platforms

This webinar describes a study that used two independent next-generation sequencing (NGS) platforms to gain insight into the impact of different types of aneuploidies during preimplantation genetic testing.

Dec

12

Featured Webinar

Precision Metagenomics to Identify Patients at Risk for Invasive Infection

This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.

Main menu